Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 3,501–3,600 of 3,704
THE EFFECTS OF GLP-1 RECEPTOR AGONISTS ON OCULAR DISEASES: A NARRATIVE REVIEW
Gąsowski, D., Dapkiewicz, E., Haba, S., Bołoz, M., Smolińska, A., Szewczyk, J., Grzyb, I., Wątek, Z., Łysynkiewicz, K., & Krawczyk, P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6144
Fat necrosis associated with glucagon-like peptide-1 receptor agonist- induced weight loss
Malik, F. A., Tanner, J., Hurley, M. Y., et al. (2026) · JAAD Case Reports · doi:10.1016/j.jdcr.2026.08.033
From adiposity to multisystem morbidity: the case for weight loss as disease modification
Sattar, N. A., Ferguson, L. D., & Lee, M. M. Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00186-5
Lavenburg, L.-M. U., Morford, H. J., Stark, S. A., Kamat, S., Mendoza, M. S., Molinari, M., & Puttarajappa, C. M. (2026) · Clinical Transplantation · doi:10.1111/ctr.70659
Smith, C. R. (2026) · Considerations in Medicine · doi:10.1136/conmed-2026-000055
Milluzzo, A., Oteri, V., Manuella, L., Pulvirenti, A., & Frittitta, L. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02189-x
Opioid Toxicity Associated With Tirzepatide in a Patient on Chronic Oral Morphine
Mataraarachchi, N. E., Dellinger, O. D., & Babakhanians, A. (2026) · Cureus · doi:10.7759/cureus.115380
Seward, M. W., Cleary, E. J., DeNovio, A. C.-J., Grimm, J. A., Curry, T. B., Beam, B. B., Hannon, C. P., & Abdel, M. P. (2026) · Arthroplasty Today · doi:10.1016/j.artd.2026.102134
Durma, A. C., Blicharska, M., & Czupryniak, L. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01913-0 · Cited by 1
ภาวะอ้วนและโรคไต: กลไกและการรักษาใหม่
ศุภศิลป์, ฐ., & สถิระพจน์, บ. (2026) · Journal of the Nephrology Society of Thailand · doi:10.63555/jnst.2026.289162
Hassan, A., Farooq, Q. U. A., Parwesh, F., Rasul, M., Masood, A., Aftab, H., Riaz, H., Mahmood, A., Malik, M. A., Rehman, A. U., et al. (2026) · F1000Research · doi:10.12688/f1000research.186847.1
Kaczynski, M., Zureikat, R. M., Kaczynski, M. R., Sitarz, R., & Karakuła‐Juchnowicz, H. (2026) · Biomedicines · doi:10.3390/biomedicines14091957
Paccola, G. P., de Oliveira, R. F., Mochetti, M. M., Razera, F. P. M., Vecchi, R., & Montanher, R. C. P. (2026) · Clinical Obesity · doi:10.1111/cob.70111 · Cited by 1
Falcón, B. L., Xie, C. C., Redline, S. S., Grunstein, R., Turnbull, C. D., Rapoport, D. M., Wang, H., Chakladar, S., Dimitriadis, G. K., Lau, E., et al. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-026-00162-z
Moiz, A., Filion, K. B., Samuels, A. E., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05519
Noe͏̈l, P., Biertho, L. D., Ponce, J., Garneau, P. Y., Lutfi, R. E., & Gagner, M. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.08.020 · Cited by 1
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
Perretta, S. (2026) · Endoscopy · doi:10.1055/a-2910-1734
Lalani, I., Nambayan, R., Carbonell, C., Ruan, Y., O'Sullivan, D. E., Stukalin, I., Hilsden, R. J., & Brenner, D. R. (2026) · Cancer Control · doi:10.1177/10732748261483767 · Cited by 1
Kim, D. W., Sheu, E. G., Nimeri, A. A., Cristancho, C., Salim, K., Shin, H., McDonnell, M. E., & Apovian, C. M. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08913-w
Felix, A. B. N., Zendram, C. D. O., Rosa, I. C. D. P., Barbosa, A. H., & Calissi, É. F. (2026) · Brazilian Journal of Science · doi:10.14295/bjs.v6i3.948
Baig, S. J., Varma, A., & Biswas, A. K. (2026) · Indian Journal of Surgery · doi:10.1007/s12262-026-04667-y
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00131-3
Lubo, C., Bustamante, R., Quintana-Espinosa, L., & Guillen-Burgos, H. F. (2026) · Brain Sciences · doi:10.3390/brainsci16090926
Choudhary, A. K., & Sahu, S. (2026) · Research Square · doi:10.21203/rs.3.rs-10780569/v1
Mikołajuk, A., Mallah, R., Kozdroń, D. J., Nieścioruk, M. W., Szczepańska, P., Kowalski, J., Dutkiewicz, D., & Yarbou, A. E. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5581
Effects of obesity on brain health and cognition
McEntee, C. M., Savelieff, M. G., Noureldein, M. H., Eid, S., Grisold, W., Hassenstab, J. J., & Feldman, E. L. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01251-6 · Cited by 2
Kalafati, I. P., Krongauz, D. L., Bosco, A., Noto, A., Piras, C., Kafyra, M., Dessì, A., Mauri, M., Atzori, L., Weinberger, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70220
Sztanek, F., Lőrincz, H., Harangi, M., & Nagy, A. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71277 · Cited by 1
Expert Consensus on the Management of Obesity in Older Adults (2026 Edition)
Pan, Q., & Guo, L. (2026) · Aging Medicine · doi:10.1002/agm2.70105
GLP-1/GIP Uptake, Indication, and Access Pathways Among US Adults in the Understanding America StudyPreprint
Chaturvedi, R. R., Gračner, T., Pérez‐Arce, F., Suen, S., Jin, J., Orriens, B., Pacula, R. L., Ward, A. S., Haile, R., & Kapteyn, A. (2026) · medRxiv · doi:10.64898/2026.08.28.26361368
Arbogast, M., Bayer, M., Biraima, M., Brunner, W., Rabl, C., Gerber, P., & Gerö, D. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100742
Emerging Topics In Obesity Treatment in the Setting of Organ Transplantation
Maahs, E. D., Zimmerman, Z., Khungar, V., & Banini, B. A. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00749-w
Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review
Harris, A., & Kaffenberger, T. M. (2026) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2026.2266 · Cited by 2
Hungund, S. (2026) · Qeios · doi:10.32388/i85yu1
Computational Platforms for Membrane-Active Peptide Therapeutic Design
Zan, B., Chen, C. H., Sabha, M., Wu, K., Kadri, M., Nwajiaku, O. L., Hoogland, D., Ulmschneider, J. P., & Ulmschneider, M. B. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.6c00100
Liu, W., Zhao, J., Zhang, D., Dang, C., Lu, Y., & Du, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1955223
The promise of biased ligands in therapeutics
Eiger, D. S., Smith, J. S., & Rajagopal, S. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100160
Lee, C.-M., Kim, J.-Y., Shim, J.-H., & Cho, G.-W. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2928-5204
Are We Asking About Tirzepatide? Emerging Oral Health Implications for Oral Medicine Practice
Miranda, D. D. A., de Arruda, J. A. A., & de Andrade, B. A. B. (2026) · Oral Diseases · doi:10.1111/odi.70484
Oral Incretin-Based Therapies for Weight Management
Cheng, H. E., Bonafede, M., & Shukla, A. P. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01456-6
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
Ahmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.52.68.79
Moscucci, F., Tocci, G., Nardoianni, G., Savoia, C., Contino, V., Leo, G., Bocale, R., Desideri, G., & Baratta, F. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00819-z
Impact of GLP-1 dose intensity on perioperative and long-term fusion outcomes following ACDF
Stirpe, C., Lee, B. H., Lavu, M. S., Ding, I., Furey, C. G., & Cheng, C. W. (2026) · The Spine Journal · doi:10.1016/j.spinee.2026.08.009
Pathophysiology and Management of Obesity
Yang, P., Lee, P., Chen, C., & Lin, M. (2026) · Springer eBooks · doi:10.1007/978-981-96-1297-0_42
Mehetre, K. N., & Dawane, J. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933913
GLP-1 Receptor Agonists and Reproductive Health
Porterfield, F., Mulligan, J., Salim, K., Olubowale, O. O., & Stanford, F. C. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.07.003 · Cited by 1
Medeot, M. (2026) · Biomedicine Advances · doi:10.34172/bma.74
AMPOFO, E., Apprey, C., Amoako, M., & Turkson, F. D. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70188
Kim, M. (2026) · Toxicology Letters · doi:10.1016/j.toxlet.2026.112949
Kim, H.-L., Kim, H., Han, Y., An, S., Boo, M., Choi, H., Park, J. I., Kim, H., Yang, H., Sim, J. H., et al. (2026) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2026.101198
Genetic Variants Associated with Response to GLP-1 Receptor Agonists in Diabetes and Obesity
Fernandes, M. T., Dias, J. C., Espírito‐Santo, M., Estêvão, M. D., & Sousa‐Coelho, A. L. D. (2026) · Life · doi:10.3390/life16091486
Qi, H., Gao, Q., Chen, H., Du, X., & Pan, B. (2026) · PeerJ · doi:10.7717/peerj.21713
Patient characteristics and early experiences with anti-obesity medications: the CAMP study
Tewksbury, C. M., Soliva, E. A., Scheffey, K., Kwong, P. L., & Glanz, K. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1931188
Patel, N., Glaysher, M. A., Carter, N. C., & van Boxel, G. (2026) · Digestive Surgery · doi:10.1159/dsu/acoag003
Is Insulin Resistance the Driver or the Outcome of Diabetes Mellitus? A Critical Review
Shahid, S., Qamar, S., Qamar, F., Fatima, A., Máthé, E., & Khaliq, M. (2026) · Journal of Nutrition and Metabolism · doi:10.1155/jnme/9614195
Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes
Vidal, J. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.009
Sun, D., Wang, X., Wang, H., Shen, Z., Meng, X., & Zhou, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933732
Cook, G. (2026) · Journal of Medical Internet Research · doi:10.2196/104227
Alhazmi, A., & le Roux, C. W. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2731087
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025 · Cited by 1
Self-citationSamuels, J. M., Williams, C. R., Patel, M. B., Self, W. H., Funk, L. M., Roumie, C. L., Spann, M. D., Northup, C. J., Ye, F., Irlmeier, R., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71320
Why Do We Lose Bone During Weight Loss: Can It Be Prevented?
Shapses, S. A., & McGuire, B. D. (2026) · Current Osteoporosis Reports · doi:10.1007/s11914-026-00984-z · Cited by 4
Park, E.-O., An, M.-R., Jung, S.-J., Park, B., Chae, S., & Lee, S. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107477
Pulsatile liraglutide on a biased tirzepatide background: a hypothesis
Kopitović, I. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1922908
Cautela, D., Valeria, I., Lombardi, A., Laratta, B., Castaldo, C. M., Balestrieri, M. L., Mocini, E., Migliaccio, S., & Tardito, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188057
Viana, D. P. D. C., Invitti, A. L., Jacobsen, L., & Schor, E. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109116
Cardiovascular effects of incretin receptor agonists: beyond glycemic control
Ravić, M. P., Srejovic, I. M., Milosavljević, I., Novakovic, J. N., Jakovljević, V., Vučićević, K., Petrovic, D., & Muric, M. D. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2026-0184
Gastric bypass and sleeve gastrectomy: Impact on cardiovascular risk factors
Benaiges, D., Pedro‐Botet, J., & Casajoana, A. (2026) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2026.500962
ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES
Wielogórska, A., Stasiak, O., Kowalik, F., & Deczkowska, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5972
Hu, J., Zhang, Y., Wang, M., Zhang, B., Zhang, B., Ke, C., Tang, C., Xia, J., Zhao, Q., Gao, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00175
Elkum, N., & Aboussekhra, A. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00760-1 · Cited by 1
Wu, R., Adapa, S., Agaliotis, M., HOCKING, S. L., & Atlantis, E. E. (2026) · Clinical Obesity · doi:10.1111/cob.70113
Lu, D., Li, N., Yuan, Z., & Gao, Y. (2026) · Clinical Obesity · doi:10.1111/cob.70112
Kassem, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71293 · Cited by 2
He, Q., Shan, H., Hu, W., Xu, H. E., & Zhao, L. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01923-5
Skeletal Muscle Dysfunction in Heart Failure
Challa, A. A., Pandey, A., Brubaker, P. H., Kitzman, D. W., Bozkurt, B., & Kalra, D. K. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103353 · Cited by 1
Tseng, T., & Chang, R. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.09.010 · Cited by 1
GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension
Al‐Ali, D., & Hajj, N. E. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113325
Lim, E., Cheng, N. C. L., & Lim, C. E. D. (2026) · Nutrition & Food Science · doi:10.1108/nfs-05-2026-0239
Myśliwczyk, D., Myśliwiec, M., Minarowska, A., & Wasilewska, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188191
Allaham, L., King, B. J., Ali, F., GUPTA, I., Metuku, R., Nieto, I., Lurie, A., Amer, F. N., Reddy, R., & Alzghoul, B. N. (2026) · Lung · doi:10.1007/s00408-026-00939-2
The Dark Side of GLP-1 Receptor Agonists: Risks and Adverse Events
Nawal, C. L., Saini, H. L., Rankawat, G., & Chejara, R. S. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1655
Obesity, incretin-based therapies, and cardiovascular disease in women
Salih, M., Sloots, Y. A. J., Hemels, M. E. W., Meems, L. M. G., Leening, M. J. G., & Ghossein‐Doha, C. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02084-0
Hegaz, M. G., Aboud, M. Y. A., Kamel, A. I. I., Naveed, M. A., Elsayad, O. G., & Sorathia, A. Z. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02538-x
Włodarczyk, A., Łagosz, H., Wites, P., Wites, K., Piotrowski, P., Jabłońska, A., Pyzik, M., Ziółkowska, K., Markusiewicz, K., & Bahyrycz, P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6101
Benedict, B. C., White-Gilliam, D., Pradhan, A., Yakdan, S. M., Hammo, A., Budd, L., Arkam, F., Tang, S. Y., Schechtman, K. B., Cheng, A. L., et al. (2026) · Pain Medicine · doi:10.1093/pm/pnag121
Wadhawan, R. (2025) · Journal of Bariatric Surgery · doi:10.4103/jbs.jbs_12_26
Himanshu, Verma, S., Yadav, S., Singh, A., Chauhan, J., Sameeksha, Sahu, K., & Mamgain, A. K. (2026) · Discover Endocrinology and Metabolism · doi:10.1007/s44417-026-00025-4
Mackey, S., Egan, C., & Elkind-Hirsch, K. E. (2026) · Therapeutic Advances in Reproductive Health · doi:10.1177/26334941261481473
Carneiro, G. R. A., Nunes, I. K. D. C., dos Santos, G. R. C., dos Santos, P. F., Padilha, M. C., Nogueira, F. C. S., & Pereira, H. M. G. (2026) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.70179
Soltani, H. R., Toolabi, K., Safavi, S. A. S., Najjari, K., & Latif, A. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08933-6
Marqués-Vidas, M., Quiroga, B., Portolés, J. M., Ortíz, A., Fernández‐Fernández, B., Horrillo, A. S., Soler, M. J., García-Carro, C., Morales, E., & Bajo, M. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187201
Klotz, T. (2026) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2943-1080
Adipocytes as a Mechanistic Link Between Incretin-Based Therapies and Hair Loss
Gupta, A. K., Kaur, J., Piguet, V., & Mirmirani, P. (2026) · Biology · doi:10.3390/biology15181642
Predictors of treatment response to semaglutide for weight management
Tzoulis, P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1893511
Beyond Weight Loss: Redefining MASLD Management Through Obesity Pharmacotherapy
Ravaioli, F. (2026) · European Medical Journal · doi:10.33590/emj/1463768r
Mizdrak, M., Batistic, D., & Mizdrak, I. (2026) · Medical Sciences · doi:10.3390/medsci14050577
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.